Clinical Trial Update: Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating topical tretinoin to prevent anti-EGFR–induced skin toxicity in patients with metastatic or locally advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• TRETINOIN (TRETINOIN)

Snippet

Sponsor: University of Utah | Conditions: Metastatic Solid Tumor, Locally Advanced Solid Tumor | Phase 2 | Status: RECRUITING